上皮性卵巢癌中BRCA1的甲基化状态与免疫组织化学
Methylation status and immunohistochemistry of BRCA1 in epithelial ovarian cancer.
作者信息
Pradjatmo Heru, Dasuki Djaswadi, Anwar Mohammad, Mubarika Sofia
机构信息
Department of Obstetric and Gynecology, Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta, Indonesia E-mail :
出版信息
Asian Pac J Cancer Prev. 2014;15(21):9479-85. doi: 10.7314/apjcp.2014.15.21.9479.
BACKGROUND
Cancer initiation and progression are controlled by genetic and epigenetic events. One epigenetic process which is widely known is DNA methylation, a cause of gene silencing. If a gene is silenced the protein which it encodes will not expressed.
OBJECTIVES
- Identify the methylation status of BRCA1 in patients with epithelial ovarian cancer (EOC)and assess BRCA1 protein expression in tumor tissue. 2. Examine whether BRCA1 gene methylation and BRCA1 protein are associated with survival of epithelial ovarian cancer patients.
METHODS
The study design was a prospective-cohort study, conducted at Sardjito hospital, Yogyakarta, Indonesia.
RESULTS
A total of 69 cases were analyzed in this study. The data showed that the methylation status of BRCA1 in EOC was positive in 89.9%, with clear protein expression of BRCA1 in 31.9%. Methylation status and expression of BRCA1 were not prognosticators of EOC patients. Menarche, CA125 level, clinical stage and residual tumor were independent factors for prognosis.
背景
癌症的发生和发展受遗传和表观遗传事件控制。一种广为人知的表观遗传过程是DNA甲基化，它是基因沉默的一个原因。如果一个基因被沉默，它所编码的蛋白质将不会表达。
目的
- 确定上皮性卵巢癌（EOC）患者中BRCA1的甲基化状态，并评估肿瘤组织中BRCA1蛋白的表达。2. 研究BRCA1基因甲基化和BRCA1蛋白是否与上皮性卵巢癌患者的生存相关。
方法
本研究为前瞻性队列研究，在印度尼西亚日惹的萨迪托医院进行。
结果
本研究共分析了69例病例。数据显示，EOC中BRCA1的甲基化状态阳性率为89.9%，BRCA1蛋白清晰表达率为31.9%。BRCA1的甲基化状态和表达不是EOC患者的预后指标。初潮、CA125水平、临床分期和残留肿瘤是预后的独立因素。
Zotero 插件